3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
4
Not yet recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
6
Rectal Neoplasms
3
Lung Neoplasms
2
Carcinoma, Hepatocellular
2
Upper Tract Urothelial Carcinoma
1
Unresectable Hepatocellular Carcinoma
1
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Solid Tumor Cancer
1
Sarcoma
1
Radiation Injuries
1
Pathologic Complete Response
1
Pancreatic Cancer Liver Metastases
1
Neoadjuvant Immunotherapy
1
Muscle-invasive Bladder Cancer
1
Locally Advanced Rectal Adenocarcinoma
1
Locally Advanced Pancreatic Cancer
1
Locally Advanced Cervical Carcinoma
1
Hyperthermia
1
HER2-Negative Locally Advanced Breast Cancer
1
Gynecologic Cancers
1
Gastrointestinal Neoplasms
1
Gastric Cancer With Liver Metastases
1
Esophageal Squamous Cell Carcinoma
1
Efficacy and Safety of Short-course Radiotherapy in Total Neoadjuvant Therapy Combined With Enlonstobart for pMMR Locally Advanced Rectal Cancer
1
Colorectal Neoplasms
1
Carcinoma
1
Breast Neoplasms
1
Advanced Rectal Cancer
1
Interventions
toripalimab
6
Cisplatin
5
130-nm albumin-bound paclitaxel
5
Drug Therapy
4
tislelizumab
3
sintilimab
3
camrelizumab
3
Injections
3
Immune Checkpoint Inhibitors
3
Fluorouracil
3
Carboplatin
3
nedaplatin
2
anlotinib
2
Radiotherapy
2
Paclitaxel
2
Neoadjuvant Therapy
2
Irinotecan
2
Esophagectomy
2
potassium oxonate
1
pembrolizumab
1
lenvatinib
1
ivarmacitinib
1
irinotecan sucrosofate
1
Watchful Waiting
1
Taxes
1
TP protocol
1
S 1 (combination)
1
Radiotherapy, Intensity-Modulated
1
Radiation
1
Observation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Esophageal Squamous Cell Carcinoma
×
Immunotherapy
×
Clear all
NCT05791136
2023-03-30
TREE
The Central Hospital of Lishui City
Phase 2
Not yet recruiting
30 enrolled